With Oliver Burghardt, we are gaining an internationally experienced leader with extensive MedTech expertise to head Human Med AG. As our new CEO, he will drive the strategic development of our company, focusing in particular on international business development, the positioning of our product portfolio and our research and development activities.
Oliver Burghardt joins us from Olympus, where he most recently served as Vice President Medical Endoscopy Group, heading the endoscopy business in the EMEA region. Prior to that, he held various international leadership positions and gained extensive experience in business development, go-to-market and organizational development.
“What appeals to me most is the opportunity to advance Human Med at a decisive stage of its strategic business development. In addition to expanding the business internationally, I see great potential in the strategic positioning of the product portfolio and in further developing our research and development activities in line with future clinical and technological requirements,” says Oliver Burghardt.
Research and clinical application at the center
With our water-jet assisted liposuction (WAL), we have a clearly differentiated technology offering high clinical benefit in reconstructive and aesthetic surgery, and particularly in the treatment of lipedema. We intend to further strengthen this technological position, tap into additional market potential and consistently expand our international business.
A particular focus is on sustainable innovation, user orientation and new therapeutic applications. The needs of surgeons are to be incorporated even more closely into development, while the clinical evidence for our technologies is strengthened further. The patient always remains at the center – with the goal of supporting the best possible treatment through our technologies.
Our aim is to develop Human Med into an internationally leading premium provider of water-jet assisted liposuction and autologous fat transfer systems – built on a strong technological and scientific foundation.
A clear leadership structure for the next phase of development
With Oliver Burghardt as CEO, Dirk Priewe-Hufmüller returns to his focus as Chief Sales Officer (CSO), taking responsibility for sales and marketing as a member of the Executive Board. In recent months, he had additionally assumed responsibility for company management and played a key role in driving the market launch of our new body-jet® neo.
With the new leadership structure, we combine international management experience with strong sales, market and industry expertise. This creates the conditions to bring innovations to market faster, further expand our international presence and consistently continue our growth trajectory.
